{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:15:36Z","timestamp":1792718136186,"version":"4.5.0"},"reference-count":103,"publisher":"ScopeMed","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":130,"URL":"https:\/\/bdvets.org\/JAVAR\/?sec=licenseinfo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.5455\/javar.2026.m1020","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:57:16Z","timestamp":1778529436000},"source":"Crossref","is-referenced-by-count":1,"title":["Nephroprotective and antioxidant properties of a novel herbal extract combination in a high-fat diet and alloxan-induced kidney injury in rats"],"prefix":"10.5455","member":"3407","reference":[{"key":"ref1","unstructured":"[1] Pang J, Chen K, Chen SY -H, Chen X. Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990\u20132019: A systematic analysis for the"},{"key":"ref2","unstructured":"GBD 2019. Diabetol Metab Syndr 2022; 14:112. [Crossref ]"},{"key":"ref3","unstructured":"[2] Younossi ZM, Golabi P , Price JW, Owrangi S, Gundu-Rao N. The global epidemiology of non-alcoholic fatty liver disease and non-alcoholic"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 2024; 22(10):1999\u20132010. [Crossref ]","DOI":"10.1016\/j.cgh.2024.03.006"},{"key":"ref5","unstructured":"[3] Shi JM, Wu X, Yu J, Dai Q, Zheng K, Feng Y, et al. Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an"},{"key":"ref6","unstructured":"analysis from the GBD 2021 and forecast to 2050. Front Nutr 2025; 12:1651357. [Crossref ]"},{"key":"ref7","unstructured":"[4] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gastroenterol Hepatol 2021; 18:223\u201338. [Crossref ]","DOI":"10.1038\/s41575-020-00381-6"},{"key":"ref9","unstructured":"[5] Sandireddy R, Sakthivel S, Gupta P , Behari J, Tripathi M, Singh BK, et al. Systemic impacts of metabolic dysfunction-associated steatotic"},{"key":"ref10","unstructured":"liver disease and metabolic dysfunction-associated steatohepatitis on heart, muscle, and kidney related diseases. Front Cell Dev Biol 2024;"},{"key":"ref11","unstructured":"12:1433857. [Crossref ]"},{"key":"ref12","unstructured":"[6] Kanbay M, Bulbul MC, Copur S, Afsar B, Sag AA, Ortiz A, et al. Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"and chronic kidney disease. J Nephrol 2021; 34:649\u201359. [Crossref ]","DOI":"10.1007\/s40620-020-00751-y"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"[7] Piko N, Bevc S, Hojs R, Ekart R. The role of oxidative stress in kidney injury. Antioxidants 2023; 12(9):1772. [Crossref ]","DOI":"10.3390\/antiox12091772"},{"key":"ref15","unstructured":"[8] Ravarotto V, Bertoldi G, Innico G, Gobbi L, Cal\u00f2 LA. The pivotal role of oxidative stress in the pathophysiology of cardiovascular-renal remodeling"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"in kidney disease. Antioxidants 2021; 10(7):1041. [Crossref ]","DOI":"10.3390\/antiox10071041"},{"key":"ref17","unstructured":"[9] Anwar S, Sarwar T , Khan AA, Rahmani AH. Therapeutic applications and mechanisms of superoxide dismutase (SOD) in different pathogenesis."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Biomolecules 2025; 15(8):1130. [Crossref ]","DOI":"10.3390\/biom15081130"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"[10] Ho HJ, Shirakawa H. Oxidative stress and mitochondrial dysfunction in chronic kidney disease. Cells 2022; 12(1):88. [Crossref ]","DOI":"10.3390\/cells12010088"},{"key":"ref20","unstructured":"[11] Nam H, Lim JH, Kim TW, Kim EN, Oum SJ, Yoon NA, et al. Extracellular superoxide dismutase attenuates hepatic oxidative stress in nonalcoholic"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"fatty liver disease through the adenosine monophosphate-activated protein kinase activation. Antioxidants 2023; 12(12):2040. [Crossref ]","DOI":"10.3390\/antiox12122040"},{"key":"ref22","unstructured":"[12] Zhong CL, Song N, Huang P , Yin Y, Zhang Y, Gao X, et al. Targeting ROS and inflammation in sepsis-induced liver injury with naturally derived"},{"key":"ref23","unstructured":"superoxide dismutase-mimicking carbon dots. Biomater Res 2025; 29:0249. [Crossref ]"},{"key":"ref24","unstructured":"[13] Sutti S, Albano E. Oxidative stress in nonalcoholic fatty liver disease: A reappraisal of the role in supporting inflammatory mechanisms. Redox"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Exp Med 2022; 2022(1):R57\u201368. [Crossref ]","DOI":"10.9785\/ag-2023-680501"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"[14] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397(10290):2212\u201324. [Crossref ]","DOI":"10.1016\/S0140-6736(20)32511-3"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"[15] Spencer SM, Desborough RA, Bhandari S. Should cystatin C eGFR become routine clinical practice? Biomolecules 2023; 13(7):1075. [Crossref ]","DOI":"10.3390\/biom13071075"},{"key":"ref28","unstructured":"[16] Xin Y, Liu Y, Liu L, Wang X, Wang D, Song Y, et al. Dynamic changes in the real-time glomerular filtration rate and kidney injury markers in"},{"key":"ref29","unstructured":"different acute kidney injury models. J Transl Med 2024; 22:867. [Crossref ]"},{"key":"ref30","unstructured":"[17] Grubb AO, Magnusson M, Christensson A. Etiologic and diagnostic implications of morbidity and mortality associations when cystatin C-based"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"estimated GFR is lower than creatinine-based estimated GFR. Am J Kidney Dis 2023; 82(5):509\u201311. [Crossref ]","DOI":"10.1053\/j.ajkd.2023.08.001"},{"key":"ref32","unstructured":"[18] Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, DeAguiar RB, et al. PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"with improvement of steatohepatitis in patients with NASH. Liver Int 2021; 41(11):2659\u201370. [Crossref ]","DOI":"10.1111\/liv.15005"},{"key":"ref34","unstructured":"[19] Huang JF, Dai CY, Huang CF, Tsai PC, Yeh ML, Hsu PY, et al. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"sensitizer in nonalcoholic steatohepatitis patients. Hepatol Int 2021; 15:1136\u201347. [Crossref ]","DOI":"10.1007\/s12072-021-10242-2"},{"key":"ref36","unstructured":"[20] Lee SM, Pusec CM, Norris GH, De Jesus A, Diaz-Ruiz A, Mu\u00f1oz-Moreno R, et al. Hepatocyte-specific loss of PPAR\u03b3 protects mice from NASH, and"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"increases the therapeutic effects of rosiglitazone in the liver. Cell Mol Gastroenterol Hepatol 2021; 11(5):1291\u2013311. [Crossref ]","DOI":"10.1016\/j.jcmgh.2021.01.003"},{"key":"ref38","unstructured":"[21] Siddiqui A, Bansal P , Pentela B, Mazumder A, Tyagi PK, Kapoor B. Protective effects of herbal agents against hepatorenal toxicity: A review. J Nat"},{"key":"ref39","unstructured":"Remedies 2024; 24(8):1621\u201332; [Crossref ]"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"[22] Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014;","DOI":"10.3389\/fphar.2013.00177"},{"key":"ref41","unstructured":"4:177. [Crossref ]"},{"key":"ref42","unstructured":"[23] Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol"},{"key":"ref43","unstructured":"Res 2000; 33(2):179\u201389. [Crossref ]"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"[24] Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine 2001; 8(5):401\u20139. [Crossref ]","DOI":"10.1078\/0944-7113-00060"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"[25] Abd Hadi NHA, Ooi FK, Kadir AA, Ahmad NS. In vivo effects of Channa striatus on humans and animals: A systematic review. Int Food Res J 2021;","DOI":"10.47836\/ifrj.28.3.01"},{"key":"ref46","unstructured":"28(3):407\u201322. [Crossref ]"},{"key":"ref47","unstructured":"[26] Sasongko H, Nugroho AE, Nurrochmad A, Rohman A. Nephroprotective effect of milkfish, patin, and snakehead fish oil by suppressing"},{"key":"ref48","unstructured":"inflammation and oxidative stress in diabetic rats. Indones J Pharm 2024; 35(1):63\u201373. [Crossref ]"},{"key":"ref49","unstructured":"[27] Saidin WAWSW, Jantan I, Wahab SMA, Jalil J, Mohd Said M, Yusoff SD, et al. Pharmacological activities and mechanisms of action of hypophyllanthin:"},{"key":"ref50","unstructured":"A review. Front Pharmacol 2023; 13:1070557. [Crossref ]"},{"key":"ref51","unstructured":"[28] Pratima H, Shiraguppi A, Joojagar P , Shah K, Cheeraladinni SS, Singh PS, et al. Phytochemical profile and hepatoprotective potentiality of"},{"key":"ref52","unstructured":"Phyllanthus genus: A review. J Pharm Pharmacol 2025; 77(2):189\u2013205. [Crossref ]"},{"key":"ref53","unstructured":"[29] Puteri AIS, Sandhika W, Hasanatuludhhiyah N. Effect of Javanese turmeric (Curcuma xanthorrhiza) extract on hepatitis model of alcohol-induced"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"mice. J Kedokt Brawijaya 2020; 31(1):48\u201353. [Crossref ]","DOI":"10.21776\/ub.jkb.2020.031.01.11"},{"key":"ref55","unstructured":"[30] Lister INE, Chiuman L, Mutia MS, Hartono H, Girsang E. Hepatoprotective effects of Curcuma xanthorrhiza extract in APAP-mediated HepG2 cells:"},{"key":"ref56","unstructured":"Modulation of cytokines, apoptosis and JNK. Iran J Basic Med Sci 2025; 28(2):234\u201341. [Crossref ]"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"www.bdvets.org\/javar Yulizal et al.  \/ J Adv Vet Anim Res, 13(1): 159\u2013169, March 2026 169","DOI":"10.5455\/javar.2026.m1020"},{"key":"ref58","unstructured":"[31] Yustisia I, Tandiari D, Cangara MH, Hamid F, Daud NAS. A high-fat, high-fructose diet induced hepatic steatosis, renal lesions, dyslipidemia, and"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"hyperuricemia in non-obese rats. Heliyon 2022; 8(10):e10896. [Crossref ]","DOI":"10.1016\/j.heliyon.2022.e10896"},{"key":"ref60","unstructured":"[32] Willett R, Tryndyak V, Hanks JB, Elkins L, Nagumalli SK, Beland FA, et al. A preclinical model of severe NASH-like liver injury by chronic"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"administration of a high-fat and high-sucrose diet in mice. Toxicol Appl Pharmacol 2024; 491:117046. [Crossref ]","DOI":"10.1016\/j.taap.2024.117046"},{"key":"ref62","unstructured":"[33] Ighodaro OM, Adeosun AM, Akinloye OA. Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"compounds and plants extracts in experimental studies. Medicina 2017; 53(6):365\u201374. [Crossref ]","DOI":"10.1016\/j.medici.2018.02.001"},{"key":"ref64","unstructured":"[34] Ahammed K, Joardar MHH, Islam MU, Yameen MB, Rahman SMM, Sharmin R. Evaluation of nephroprotective and cytotoxic effect of ethanolic"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"extract of Mikania scandens leaves by using alloxan-induced diabetic nephropathy mice. Clin Phytosci 2020; 6:20. [Crossref ]","DOI":"10.1186\/s40816-020-00164-1"},{"key":"ref66","unstructured":"[35] Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"sciences. Behav Res Methods 2007; 39:175\u201391. [Crossref ]","DOI":"10.3758\/BF03193146"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"[36] Prendergast BJ, Onishi KG, Zucker I. Female mice liberated for inclusion in neuroscience and biomedical research. Neurosci Biobehav Rev 2014;","DOI":"10.1016\/j.neubiorev.2014.01.001"},{"key":"ref69","unstructured":"40:1\u20135. [Crossref ]"},{"key":"ref70","unstructured":"[37] Gaskill BN, Gordon CJ, Pajor EA, Lucas JR, Davis JK, Garner JP . Impact of nesting material on mouse body temperature and physiology. Physiol"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Behav 2013; 110\u201311:87\u201395. [Crossref ]","DOI":"10.15823\/p.2013.1823"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"[38] Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22(3):659\u201361. [Crossref ]","DOI":"10.1096\/fj.07-9574LSF"},{"key":"ref73","unstructured":"[39] Karabas KM, Ayhan M, Guney E, Serter M, Meteoglu I. The effect of pioglitazone on antioxidant levels and renal histopathology in streptozotocin-"},{"key":"ref74","unstructured":"induced diabetic rats. ISRN Endocrinol 2013; 2013:858690. [Crossref ]"},{"key":"ref75","unstructured":"[40] P\u00e9rez-Villalobos MC, Barba-Gonz\u00e1lez A, Garc\u00eda-Carrillo N, Mu\u00f1oz-Ortega MH, S\u00e1nchez-Alem\u00e1n E, Avila-Blanco ME, et al. Nephroprotective effect"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"of pioglitazone in a Wistar rat model of adenineinduced chronic kidney disease. Exp Ther Med 2024; 28:392. [Crossref ]","DOI":"10.3892\/etm.2024.12681"},{"key":"ref77","unstructured":"[41] Civelek E, Karaman EF, \u00d6zden S, Do\u011fan UBS, Durman KD. Effect of pioglitazone on endoplasmic reticulum stress and autophagy response in the"},{"key":"ref78","unstructured":"perivascular adipose tissue of type 2 diabetic rats. PPAR Res 2025; 2025:9645836. [Crossref ]"},{"key":"ref79","unstructured":"[42] Medi\u0107 B, Stojanovi\u0107 M, Rov\u010danin B, Keki\u0107 D, \u0160kodri\u0107 SR, Jovanovic GB, et al. Pioglitazone attenuates kidney injury in an experimental model of"},{"key":"ref80","unstructured":"gentamicin-induced nephrotoxicity in rats. Sci Rep 2019; 9:13689. [Crossref ]"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"[43] Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother 2010; 1(2):87\u201393.","DOI":"10.4103\/0976-500X.72350"},{"key":"ref82","unstructured":"[Crossref ]"},{"key":"ref83","unstructured":"[44] Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark"},{"key":"ref84","unstructured":"Insights 2016; 11:95\u2013104. [Crossref ]"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"[45] Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc 2014; 2014(6):655\u20138.","DOI":"10.1101\/pdb.prot073411"},{"key":"ref86","unstructured":"[Crossref ]"},{"key":"ref87","unstructured":"[46] Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT , Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Nephrol 2010; 21(4):556\u201363. [Crossref ]","DOI":"10.1093\/yiel\/yvs061"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"[47] Ghasemi A, Zahediasl S. Normality tests for statistical analysis: A guide for non-statisticians. Int J Endocrinol Metab 2012; 10(2):486\u20139. [Crossref ]","DOI":"10.5812\/ijem.3505"},{"key":"ref90","unstructured":"[48] Li H, Toth E, Cherrington NJ. Asking the right questions with animal models: Methionine- and choline-deficient model in predicting adverse drug"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"reactions in human NASH. Toxicol Sci 2018; 161(1):23\u201333. [Crossref ]","DOI":"10.1093\/toxsci\/kfx253"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"[49] Bent S, Ko R. Commonly used herbal medicines in the United States: A review. Am J Med 2004; 116(7):478\u201385. [Crossref ]","DOI":"10.1016\/j.amjmed.2003.10.036"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"[50] David AVA, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn Rev 2016;","DOI":"10.4103\/0973-7847.194044"},{"key":"ref94","unstructured":"10(20):84\u20139. [Crossref ]"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"[51] Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease a starter\u2019s guide. Nutrients 2017; 9(10):1072.","DOI":"10.3390\/nu9101072"},{"key":"ref96","unstructured":"[Crossref ]"},{"key":"ref97","unstructured":"[52] Machado MV, Michelotti GA, Xie G, Almeida PT , Boursier J, Bohnic B, et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"the heterogeneity of the human disease. PLoS One 2015; 10(6):e0132315. [Crossref ]","DOI":"10.1371\/journal.pone.0132315"},{"key":"ref99","unstructured":"[53] Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease."},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Hepatology 2013; 58(4):1497\u2013507. [Crossref ]","DOI":"10.1002\/hep.26226"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"[54] Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355(9198):134\u20138. [Crossref ]","DOI":"10.1016\/S0140-6736(99)06457-0"},{"key":"ref102","unstructured":"Disclaimer\/Publisher\u2019s Note: \u2002The views and data expressed are solely those of the author(s) and contributor(s) and not of the publisher or editor(s)."},{"key":"ref103","unstructured":"The publisher and editor(s) are not responsible for any injury or damage arising from the ideas, methods, instructions, or products mentioned."}],"container-title":["Journal of Advanced Veterinary and Animal Research"],"original-title":[],"link":[{"URL":"https:\/\/www.bibliomed.org\/fulltextpdf.php?mno=301595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:52:10Z","timestamp":1792677130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bibliomed.org\/?mno=301595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":103,"URL":"https:\/\/doi.org\/10.5455\/javar.2026.m1020","relation":{},"ISSN":["2311-7710"],"issn-type":[{"value":"2311-7710","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}